Inspira Technologies Oxy B.H.N. Ltd. Warrant - IINNW STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Warrant news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Warrant stock.

Inspira Technologies Oxy BHN Ltd is a specialty medical device company focused on developing innovative respiratory support technology as an alternative to mechanical ventilation. By 2020, over 600,000 patients in the U.S. will need mechanical ventilation, with a significant portion requiring ICU admission, costing an estimated $64 billion annually. The company's OxyLink technology, an advanced nano vesicle device, introduces an intravascular oxygenation system to enhance blood oxygen levels and reduce carbon dioxide, enabling physicians to address primary ventilatory conditions effectively.

The company has recently received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System. Inspira Technologies aims to revolutionize the respiratory care market with its innovative products, including the INSPIRA ART (Gen 2) system designed to elevate patient oxygen levels and potentially reduce the need for mechanical ventilation, providing new treatment alternatives and enhancing patient care.

12/28/2023 04:01 PM

News

Inspira™ Technologies Closes on $3.88 Million Registered Direct Offering

Rhea-AI Summary

Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has closed a registered direct offering of 3,031,250 ordinary shares at a purchase price of $1.28 per share, with aggregate gross proceeds of approximately $3.88 million. The company also issued warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.75%

Tags

12/26/2023 02:16 PM

News

Inspira Announces $3.88 Million Registered Direct Offering

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) has entered into a definitive agreement for the issuance and sale of 3,031,250 ordinary shares at a purchase price of $1.28 per share in a registered direct offering. The company will also issue unregistered warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.72%

Tags

12/26/2023 08:45 AM

News

Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024

Rhea-AI Summary

Inspira Technologies OXY BHN Ltd. (NASDAQ: IINN) Announces Breakthrough in Sensor Technology for Real-Time Blood Monitoring

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.72%

Tags

12/18/2023 08:30 AM

News

Inspira Technologies to Participate in J.P. Morgan Healthcare Conference

Rhea-AI Summary

Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) is set to attend the 42nd Annual J.P. Morgan Healthcare Conference in January 2024. The Company's CEO and President will meet with medical device and strategic consulting companies, aiming to advance their groundbreaking life support technology. The expected FDA clearance for their innovative life support device that directly oxygenates blood is a significant milestone on the horizon.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

Tags

12/11/2023 09:00 AM

News

In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil, a distinguished specialist in cardiac surgery and intensive care medicine, is expected to significantly contribute to the deployment of the INSPIRA™ ART100. U.S. Food and Drug Administration (FDA) approval is expected in the first half of 2024. The company is leading the way in transforming life-support care, with innovative solutions that pave the way for direct blood oxygenation and AI-driven monitoring systems, potentially enhancing patient outcomes and streamlining hospital operations.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.9%

Tags

11/29/2023 09:02 AM

News

Inspira Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) announces partnership with Ennocure MedTech Ltd. to develop bio-electronic technology for bloodstream infection prevention. The company aims to revolutionize life support technology by integrating oxygenation and infection prevention solutions, potentially improving patient outcomes and reducing healthcare costs.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.9%

Tags

11/16/2023 09:40 AM

News

Inspira™ Technologies Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) Announces Q3 Financial Results and Progress in Novel Oxygenation Technology Development

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2%

Tags

11/06/2023 09:02 AM

News

Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology

Rhea-AI Summary

Inspira Technologies has received a grant from the Israeli Innovation Authority for its VORTX Disposable Blood Oxygenation Technology. The VORTX is designed to oxygenate blood and remove carbon dioxide, addressing a $4 billion perfusion disposable market in the medical devices sector. The grant covers 40% of the first-year approved budget of $1 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.79%

Tags

10/25/2023 08:30 AM

News

Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device

Rhea-AI Summary

Inspira Technologies receives additional patent for respiratory medical device, INSPIRA ART500

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.63%

Tags

10/24/2023 08:30 AM

News

Inspira™ Terminates ATM Program and Provides an Update

Rhea-AI Summary

Inspira Technologies terminates its at-the-market equity offering program. Operations unaffected by ongoing war.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.15%

Tags

FAQ

What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW)?

The current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW) is $0.29 as of September 13, 2024.

What is Inspira Technologies Oxy BHN Ltd known for?

Inspira Technologies specializes in developing respiratory support technology as an alternative to mechanical ventilation.

What is the significance of OxyLink technology?

OxyLink is an advanced intravascular oxygenation apparatus that enhances blood oxygen levels and reduces carbon dioxide, facilitating effective treatment of ventilatory conditions.

What recent FDA clearance has Inspira Technologies received?

Inspira Technologies has received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System.

How does the INSPIRA ART (Gen 2) system aim to revolutionize patient care?

The INSPIRA ART (Gen 2) system is designed to elevate patient oxygen levels, potentially reducing the need for mechanical ventilation and offering new treatment alternatives.

What is the core mission of Inspira Technologies?

Inspira Technologies aims to enhance patient care by developing innovative medical technologies that address critical respiratory needs and revolutionize the life support arena.